VEA
AVBP icon

Virtus ETF Advisers’s ArriVent BioPharma AVBP Stock Holding History

Virtus ETF Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,747
Closed -$73.2K – 813
2024
Q4 		$73.2K Buy
+2,747
New +$78.9K 0.03% 352

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtus ETF Advisers's AVBP Position: Q1 2025 in Review

Virtus ETF Advisers sold out of ArriVent BioPharma (AVBP) in Q1 2025, closing a stake of 2,747 shares — an estimated $73.2K sold.

Virtus ETF Advisers first reported a position in AVBP in Q4 2024 and held it in 1 quarter. The position peaked at $73.2K in Q4 2024. 83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

  • Virtus ETF Advisers reported no remaining ArriVent BioPharma position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,747 ArriVent BioPharma shares in Q1 2025, an estimated $73.2K.
  • Virtus ETF Advisers first reported a position in ArriVent BioPharma in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's ArriVent BioPharma position peaked at $73.2K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.